09.23.13
In June this year, Jerusalem, Israel-based RegeneCure Ltd. released Bonecure, a membrane designed to treat bone fractures—in animals. But based on this platform, the company is developing a technology that can be used in the same way in humans.
“Based on the outstanding safety and efficacy results of our clinical and pre-clinical studies, we expect BoneCure to enable veterinary surgeons to treat a larger number of severe fracture types and to significantly reduce the healing time and complication rate,” said Moshe Tzabari, CEO of RegeneCure.
The use of the BoneCure membrane for carpal arthrodesis in animals is, according to company officials, a major breakthrough in the surgery of companion animals that offers many advantages over the traditional gold standard procedure of harvesting an autogenous bone graft. A BoneCure implant, according to the company, prevents patient (that is, animal patient) morbidity and pain, reduces the risks of infection and fracture at the donor site, saves operating time and eliminates the need for a second incision.
The membrane works by being rolled into a sleeve-shape and then placed in the space of a bone break where new bone is hoped to grow. The membrane is kept in place by bolts and sutures. It is made from microporous AMCA (ammonia methacrylate copolymer type A), the same synthetic material used to coat slow-release Aspirin, and works by disintegrating slowly as new bone forms. The microporous surface of the membrane is meant to facilitate the adherence of mesenchymal cells, or stem cells, recruited to the injured site through a signaling mechanism known as chemotaxis. In this way, bone cells scaffold onto the membrane and form new tissue.
The safety of the material has been proven scientifically and has been used for the past 35 years for other medical purposes.
The new product in development for humans is not yet named, but RegeneCure is targeting the dental implant and orthopedics markets based on clinical trial results due out this fall. The study evaluated the membrane’s ability to grow jawbone for dental implants.
“We hope that in this trial of 40 randomized patients, 20 with and 20 without our technology, that we can prove the acceleration of bone augmentation, and reach that 43 percent improvement endpoint that we claim,” said Harry Langbeheim, vice president of business development at RegeneCure.”
About 500 existing companies in the dental market, says Langbeheim, rely on collagen––a protein-based scaffold that comes from cows or pigs and is not compatible in all people. RegeneCure still needs to prove that its unique technology, classified as a medical device, will help bone re-grow faster.
“Based on the outstanding safety and efficacy results of our clinical and pre-clinical studies, we expect BoneCure to enable veterinary surgeons to treat a larger number of severe fracture types and to significantly reduce the healing time and complication rate,” said Moshe Tzabari, CEO of RegeneCure.
The use of the BoneCure membrane for carpal arthrodesis in animals is, according to company officials, a major breakthrough in the surgery of companion animals that offers many advantages over the traditional gold standard procedure of harvesting an autogenous bone graft. A BoneCure implant, according to the company, prevents patient (that is, animal patient) morbidity and pain, reduces the risks of infection and fracture at the donor site, saves operating time and eliminates the need for a second incision.
The membrane works by being rolled into a sleeve-shape and then placed in the space of a bone break where new bone is hoped to grow. The membrane is kept in place by bolts and sutures. It is made from microporous AMCA (ammonia methacrylate copolymer type A), the same synthetic material used to coat slow-release Aspirin, and works by disintegrating slowly as new bone forms. The microporous surface of the membrane is meant to facilitate the adherence of mesenchymal cells, or stem cells, recruited to the injured site through a signaling mechanism known as chemotaxis. In this way, bone cells scaffold onto the membrane and form new tissue.
The safety of the material has been proven scientifically and has been used for the past 35 years for other medical purposes.
The new product in development for humans is not yet named, but RegeneCure is targeting the dental implant and orthopedics markets based on clinical trial results due out this fall. The study evaluated the membrane’s ability to grow jawbone for dental implants.
“We hope that in this trial of 40 randomized patients, 20 with and 20 without our technology, that we can prove the acceleration of bone augmentation, and reach that 43 percent improvement endpoint that we claim,” said Harry Langbeheim, vice president of business development at RegeneCure.”
About 500 existing companies in the dental market, says Langbeheim, rely on collagen––a protein-based scaffold that comes from cows or pigs and is not compatible in all people. RegeneCure still needs to prove that its unique technology, classified as a medical device, will help bone re-grow faster.